Alteogen Inc.
196170
주식 순위
#1729
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
주가
$174.43
시가총액
$12.14B
변동 (1일)
5.32%
변동 (1년)
-44.70%
국가
KR
거래 Alteogen Inc. (196170)
카테고리
Healthcare
Alteogen Inc. (196170)의 주가 이력
최고 종가: $166.16 (2026-10-01 기준)
최저 종가: $3.00 (2014-12-01 기준)
최저 종가: $3.00 (2014-12-01 기준)
Alteogen Inc.의 주가 이력 (2014 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | -17.41% |
| 2025 | 48.44% |
| 2024 | 250.17% |
| 2023 | 104.34% |
| 2022 | -46.14% |
| 2021 | -36.60% |
| 2020 | 507.66% |
| 2019 | 109.12% |
| 2018 | 18.35% |
| 2017 | 66.19% |
| 2016 | -22.35% |
| 2015 | 47.98% |
| 2014 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $536.47 | 25.80% |
US
|
|
| $187.21 | 597.24% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $883.47 | 8.51% |
NL
|
